NovaBridge Biosciences — Net Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/32830812-e999-49ef-a51b-3b035831dfc4/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-46.3M | 2025-01-01 – 2025-12-31 | evidence 0001778016-26-000002 |
| FY 2024 | $-22.2M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-050344 |
| FY 2023 | $-207.7M | 2023-01-01 – 2023-12-31 | evidence 0000950170-25-050344 |
| FY 2022 | $-371.1M | 2022-01-01 – 2022-12-31 | evidence 0000950170-25-050344 |
| FY 2021 | $-365.9M | 2021-01-01 – 2021-12-31 | evidence 0001193125-22-133550 |
| FY 2020 | $72.2M | 2020-01-01 – 2020-12-31 | evidence 0001193125-21-135440 |
| FY 2019 | $-208.6M | 2019-01-01 – 2019-12-31 | evidence 0001193125-20-124785 |
| FY 2018 | — | 2018-01-01 – 2018-12-31 | evidence 0001193125-20-124785 |
| FY 2017 | — | 2017-01-01 – 2017-12-31 | evidence 0001193125-20-124785 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
NovaBridge Biosciences — all facts · Revenue · Operating Income